Neurology & CNS Therapeutics · Prescription Drugs
Biogen revenue, results and funding
Biogen filed revenue of $9.9B for 2025.
Data updated Nov 21, 2026 · Back to the company report
$9.9BRevenue, 2025
$1.3BNet income, 2025
BIIBNasdaq
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $9.9B | $1.3B | $29.4B | $864M | $263.6M | – | $153.8M | $290.8M | $1.8B | – | – | $6.3B | – |
| 2024 | $9.7B | $1.6B | $28B | $355.1M | $273.8M | $0 | $153.7M | $291.2M | $2B | – | – | $6.3B | $1.1B |
| 2023 | $9.8B | $1.2B | $26.8B | $740.7M | $135.3M | $0 | $277M | $264.2M | $2.4B | – | – | $6.9B | $6.9B |
| 2022 | $10.2B | $3B | $24.6B | $932.9M | $632.8M | $750M | $240.3M | $254.1M | $2.2B | – | – | $6.3B | – |
| 2021 | $11B | $1.6B | $23.9B | $247.9M | $52.5M | $1.8B | $258.1M | $238.6M | $2.5B | $2.8B | – | $6.3B | – |
| 2020 | $13.4B | $4B | $24.6B | $906.7M | $992.3M | $6.7B | $424.8M | $198.3M | $4B | $4.6B | – | $7.4B | – |
| 2019 | $14.4B | $5.9B | $27.2B | $1.1B | $1.2B | $5.9B | $514.5M | $182.3M | $2.3B | $7B | $2.9B | $4.5B | $744.4M |
| 2018 | $13.5B | $4.4B | $25.3B | $1B | $1.4B | $4.4B | $770.6M | $157.5M | $2.6B | $5.9B | $1.2B | $5.9B | $0 |
| 2017 | $12.3B | $2.5B | $23.7B | $1.1B | $2.5B | $1.4B | $867.4M | $128M | $2.3B | $5.3B | $1.6B | $5.9B | $0 |
| 2016 | $11.4B | $3.7B | $22.9B | $1.6B | $1.2B | $1B | $616.1M | $154.8M | $2B | $5.2B | $2.3B | $6.5B | $0 |
| 2015 | $10.8B | $3.5B | $19.5B | $1.7B | $1.2B | $5B | $643M | $161.4M | $2B | $4.9B | $1.3B | $6.5B | $198.8M |
| 2014 | $9.7B | $2.9B | $14.3B | $1.2B | $989.9M | $886.8M | $287.8M | $155.3M | $1.9B | $4B | $1.2B | $580.3M | $0 |
| 2013 | $6.9B | $1.9B | $11.9B | $643.2M | $601M | $400.3M | $246.3M | $136.3M | $1.4B | $2.5B | $602.6M | $592.4M | $0 |
| 2012 | $5.5B | $1.4B | $10.1B | $526.6M | $470.6M | $984.7M | $254.5M | $118.6M | $1.3B | $1.9B | $570.7M | $687.4M | $72.4M |
| 2011 | $5B | $1.2B | $9B | $332.7M | $444.5M | $498M | $208M | $113M | $1.2B | $1.7B | $514.5M | $1B | $5M |
Sources: SEC
How to cite
Biogen, Financials. Alion, Nov 21, 2026. https://alion.io/company/biogen-2/financials
